Low-Dose Radiation Therapy (2 Gy × 2) in the Treatment of Orbital Lymphoma

Purpose Low-dose radiation has become increasingly used in the management of indolent non-Hodgkin lymphoma (NHL), but has not been studied specifically for cases of ocular adnexal involvement. The objective of this study is to investigate the effectiveness of low-dose radiation in the treatment of N...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of radiation oncology, biology, physics biology, physics, 2013-08, Vol.86 (5), p.930-935
Hauptverfasser: Fasola, Carolina E., MD, MPH, Jones, Jennifer C., MD, PhD, Huang, Derek D., MD, Le, Quynh-Thu, MD, Hoppe, Richard T., MD, Donaldson, Sarah S., MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 935
container_issue 5
container_start_page 930
container_title International journal of radiation oncology, biology, physics
container_volume 86
creator Fasola, Carolina E., MD, MPH
Jones, Jennifer C., MD, PhD
Huang, Derek D., MD
Le, Quynh-Thu, MD
Hoppe, Richard T., MD
Donaldson, Sarah S., MD
description Purpose Low-dose radiation has become increasingly used in the management of indolent non-Hodgkin lymphoma (NHL), but has not been studied specifically for cases of ocular adnexal involvement. The objective of this study is to investigate the effectiveness of low-dose radiation in the treatment of NHL of the ocular adnexa. Methods and Materials We reviewed the records of 20 NHL patients with 27 sites of ocular adnexal involvement treated with low-dose radiation consisting of 2 successive fractions of 2 Gy at our institution between 2005 and 2011. The primary endpoint of this study is freedom from local relapse (FFLR). Results At a median follow-up time of 26 months (range 7-92), the overall response rate for the 27 treated sites was 96%, with a complete response (CR) rate of 85% (n=23) and a partial response rate of 11% (n=3). Among all treated sites with CR, the 2-year FFLR was 100%, with no in-treatment field relapses. The 2-year freedom from regional relapse rate was 96% with 1 case of relapse within the ipsilateral orbit (outside of the treatment field). This patient underwent additional treatment with low-dose radiation of 4 Gy to the area of relapse achieving a CR and no evidence of disease at an additional 42 months of follow-up. Orbital radiation was well tolerated with only mild acute side effects (dry eye, conjunctivitis, transient periorbital edema) in 30% of treated sites without any reports of long-term toxicity. Conclusions Low-dose radiation with 2 Gy × 2 is effective and well tolerated in the treatment of indolent NHL of the ocular adnexa with high response rates and durable local control with the option of reirradiation in the case of locoregional relapse.
doi_str_mv 10.1016/j.ijrobp.2013.04.035
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7560946</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0360301613004641</els_id><sourcerecordid>1399934306</sourcerecordid><originalsourceid>FETCH-LOGICAL-c645t-724ff6d2a251b1b827db707e0726d815c4178871ca1cf0d37439c858eb6d0ddb3</originalsourceid><addsrcrecordid>eNqFUsuO1DAQjBCIHRb-ACFLXJZDhvYjcXJBQgssiJFWgkHiZjl2h3hI4mBnFs2X8EH8GI5mWR6XPfng6qquqs6yxxTWFGj5fLd2u-Cbac2A8jWINfDiTrailaxzXhSf72Yr4CXkPIFPsgcx7gCAUinuZyeMS1YCsFX2fuO_5698RPJBW6dn50ey7TDo6UDOGLk4kJ8_CHtG3EjmDsk2oJ4HHGfiW3IZGjfrnmwOw9T5QT_M7rW6j_jo-j3NPr15vT1_m28uL96dv9zkphTFnEsm2ra0TLOCNrSpmLSNBImQdrIVLYygsqokNZqaFiyXgtemKipsSgvWNvw0e3HknfbNgNakdYLu1RTcoMNBee3Uvz-j69QXf6VkUUItykTw9Ejg4-xUNG5G0xk_jmhmxRgrZcWrhDq7lgn-2x7jrAYXDfa9HtHvo6KJjTIBIG6H8rquueCwaIsj1AQfY8D2Zm8KailW7dSxWLUUq0CoVGwae_K355uh303-CQVT8lcOw-ILR4PWhcWW9e42hf8JTO9GZ3T_FQ8Yd34fxtSqoioyBerjclzLbVGeEigF5b8A-5HJBg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1399934306</pqid></control><display><type>article</type><title>Low-Dose Radiation Therapy (2 Gy × 2) in the Treatment of Orbital Lymphoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Fasola, Carolina E., MD, MPH ; Jones, Jennifer C., MD, PhD ; Huang, Derek D., MD ; Le, Quynh-Thu, MD ; Hoppe, Richard T., MD ; Donaldson, Sarah S., MD</creator><creatorcontrib>Fasola, Carolina E., MD, MPH ; Jones, Jennifer C., MD, PhD ; Huang, Derek D., MD ; Le, Quynh-Thu, MD ; Hoppe, Richard T., MD ; Donaldson, Sarah S., MD</creatorcontrib><description>Purpose Low-dose radiation has become increasingly used in the management of indolent non-Hodgkin lymphoma (NHL), but has not been studied specifically for cases of ocular adnexal involvement. The objective of this study is to investigate the effectiveness of low-dose radiation in the treatment of NHL of the ocular adnexa. Methods and Materials We reviewed the records of 20 NHL patients with 27 sites of ocular adnexal involvement treated with low-dose radiation consisting of 2 successive fractions of 2 Gy at our institution between 2005 and 2011. The primary endpoint of this study is freedom from local relapse (FFLR). Results At a median follow-up time of 26 months (range 7-92), the overall response rate for the 27 treated sites was 96%, with a complete response (CR) rate of 85% (n=23) and a partial response rate of 11% (n=3). Among all treated sites with CR, the 2-year FFLR was 100%, with no in-treatment field relapses. The 2-year freedom from regional relapse rate was 96% with 1 case of relapse within the ipsilateral orbit (outside of the treatment field). This patient underwent additional treatment with low-dose radiation of 4 Gy to the area of relapse achieving a CR and no evidence of disease at an additional 42 months of follow-up. Orbital radiation was well tolerated with only mild acute side effects (dry eye, conjunctivitis, transient periorbital edema) in 30% of treated sites without any reports of long-term toxicity. Conclusions Low-dose radiation with 2 Gy × 2 is effective and well tolerated in the treatment of indolent NHL of the ocular adnexa with high response rates and durable local control with the option of reirradiation in the case of locoregional relapse.</description><identifier>ISSN: 0360-3016</identifier><identifier>ISSN: 1879-355X</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2013.04.035</identifier><identifier>PMID: 23726002</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; EDEMA ; Female ; Follow-Up Studies ; Hematology, Oncology and Palliative Medicine ; Humans ; Lymphoma - radiotherapy ; Lymphoma, Non-Hodgkin - radiotherapy ; LYMPHOMAS ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Orbital Neoplasms - radiotherapy ; PATIENTS ; RADIATION DOSES ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOTHERAPY ; Radiotherapy Dosage ; Remission Induction ; REVIEWS ; SIDE EFFECTS ; TOXICITY</subject><ispartof>International journal of radiation oncology, biology, physics, 2013-08, Vol.86 (5), p.930-935</ispartof><rights>Elsevier Inc.</rights><rights>2013 Elsevier Inc.</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c645t-724ff6d2a251b1b827db707e0726d815c4178871ca1cf0d37439c858eb6d0ddb3</citedby><cites>FETCH-LOGICAL-c645t-724ff6d2a251b1b827db707e0726d815c4178871ca1cf0d37439c858eb6d0ddb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2013.04.035$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,777,781,882,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23726002$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22267838$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Fasola, Carolina E., MD, MPH</creatorcontrib><creatorcontrib>Jones, Jennifer C., MD, PhD</creatorcontrib><creatorcontrib>Huang, Derek D., MD</creatorcontrib><creatorcontrib>Le, Quynh-Thu, MD</creatorcontrib><creatorcontrib>Hoppe, Richard T., MD</creatorcontrib><creatorcontrib>Donaldson, Sarah S., MD</creatorcontrib><title>Low-Dose Radiation Therapy (2 Gy × 2) in the Treatment of Orbital Lymphoma</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose Low-dose radiation has become increasingly used in the management of indolent non-Hodgkin lymphoma (NHL), but has not been studied specifically for cases of ocular adnexal involvement. The objective of this study is to investigate the effectiveness of low-dose radiation in the treatment of NHL of the ocular adnexa. Methods and Materials We reviewed the records of 20 NHL patients with 27 sites of ocular adnexal involvement treated with low-dose radiation consisting of 2 successive fractions of 2 Gy at our institution between 2005 and 2011. The primary endpoint of this study is freedom from local relapse (FFLR). Results At a median follow-up time of 26 months (range 7-92), the overall response rate for the 27 treated sites was 96%, with a complete response (CR) rate of 85% (n=23) and a partial response rate of 11% (n=3). Among all treated sites with CR, the 2-year FFLR was 100%, with no in-treatment field relapses. The 2-year freedom from regional relapse rate was 96% with 1 case of relapse within the ipsilateral orbit (outside of the treatment field). This patient underwent additional treatment with low-dose radiation of 4 Gy to the area of relapse achieving a CR and no evidence of disease at an additional 42 months of follow-up. Orbital radiation was well tolerated with only mild acute side effects (dry eye, conjunctivitis, transient periorbital edema) in 30% of treated sites without any reports of long-term toxicity. Conclusions Low-dose radiation with 2 Gy × 2 is effective and well tolerated in the treatment of indolent NHL of the ocular adnexa with high response rates and durable local control with the option of reirradiation in the case of locoregional relapse.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>EDEMA</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Lymphoma - radiotherapy</subject><subject>Lymphoma, Non-Hodgkin - radiotherapy</subject><subject>LYMPHOMAS</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Orbital Neoplasms - radiotherapy</subject><subject>PATIENTS</subject><subject>RADIATION DOSES</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>RADIOTHERAPY</subject><subject>Radiotherapy Dosage</subject><subject>Remission Induction</subject><subject>REVIEWS</subject><subject>SIDE EFFECTS</subject><subject>TOXICITY</subject><issn>0360-3016</issn><issn>1879-355X</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUsuO1DAQjBCIHRb-ACFLXJZDhvYjcXJBQgssiJFWgkHiZjl2h3hI4mBnFs2X8EH8GI5mWR6XPfng6qquqs6yxxTWFGj5fLd2u-Cbac2A8jWINfDiTrailaxzXhSf72Yr4CXkPIFPsgcx7gCAUinuZyeMS1YCsFX2fuO_5698RPJBW6dn50ey7TDo6UDOGLk4kJ8_CHtG3EjmDsk2oJ4HHGfiW3IZGjfrnmwOw9T5QT_M7rW6j_jo-j3NPr15vT1_m28uL96dv9zkphTFnEsm2ra0TLOCNrSpmLSNBImQdrIVLYygsqokNZqaFiyXgtemKipsSgvWNvw0e3HknfbNgNakdYLu1RTcoMNBee3Uvz-j69QXf6VkUUItykTw9Ejg4-xUNG5G0xk_jmhmxRgrZcWrhDq7lgn-2x7jrAYXDfa9HtHvo6KJjTIBIG6H8rquueCwaIsj1AQfY8D2Zm8KailW7dSxWLUUq0CoVGwae_K355uh303-CQVT8lcOw-ILR4PWhcWW9e42hf8JTO9GZ3T_FQ8Yd34fxtSqoioyBerjclzLbVGeEigF5b8A-5HJBg</recordid><startdate>20130801</startdate><enddate>20130801</enddate><creator>Fasola, Carolina E., MD, MPH</creator><creator>Jones, Jennifer C., MD, PhD</creator><creator>Huang, Derek D., MD</creator><creator>Le, Quynh-Thu, MD</creator><creator>Hoppe, Richard T., MD</creator><creator>Donaldson, Sarah S., MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope><scope>OTOTI</scope><scope>5PM</scope></search><sort><creationdate>20130801</creationdate><title>Low-Dose Radiation Therapy (2 Gy × 2) in the Treatment of Orbital Lymphoma</title><author>Fasola, Carolina E., MD, MPH ; Jones, Jennifer C., MD, PhD ; Huang, Derek D., MD ; Le, Quynh-Thu, MD ; Hoppe, Richard T., MD ; Donaldson, Sarah S., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c645t-724ff6d2a251b1b827db707e0726d815c4178871ca1cf0d37439c858eb6d0ddb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>EDEMA</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Lymphoma - radiotherapy</topic><topic>Lymphoma, Non-Hodgkin - radiotherapy</topic><topic>LYMPHOMAS</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Orbital Neoplasms - radiotherapy</topic><topic>PATIENTS</topic><topic>RADIATION DOSES</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>RADIOTHERAPY</topic><topic>Radiotherapy Dosage</topic><topic>Remission Induction</topic><topic>REVIEWS</topic><topic>SIDE EFFECTS</topic><topic>TOXICITY</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fasola, Carolina E., MD, MPH</creatorcontrib><creatorcontrib>Jones, Jennifer C., MD, PhD</creatorcontrib><creatorcontrib>Huang, Derek D., MD</creatorcontrib><creatorcontrib>Le, Quynh-Thu, MD</creatorcontrib><creatorcontrib>Hoppe, Richard T., MD</creatorcontrib><creatorcontrib>Donaldson, Sarah S., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>OSTI.GOV</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fasola, Carolina E., MD, MPH</au><au>Jones, Jennifer C., MD, PhD</au><au>Huang, Derek D., MD</au><au>Le, Quynh-Thu, MD</au><au>Hoppe, Richard T., MD</au><au>Donaldson, Sarah S., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low-Dose Radiation Therapy (2 Gy × 2) in the Treatment of Orbital Lymphoma</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2013-08-01</date><risdate>2013</risdate><volume>86</volume><issue>5</issue><spage>930</spage><epage>935</epage><pages>930-935</pages><issn>0360-3016</issn><issn>1879-355X</issn><eissn>1879-355X</eissn><abstract>Purpose Low-dose radiation has become increasingly used in the management of indolent non-Hodgkin lymphoma (NHL), but has not been studied specifically for cases of ocular adnexal involvement. The objective of this study is to investigate the effectiveness of low-dose radiation in the treatment of NHL of the ocular adnexa. Methods and Materials We reviewed the records of 20 NHL patients with 27 sites of ocular adnexal involvement treated with low-dose radiation consisting of 2 successive fractions of 2 Gy at our institution between 2005 and 2011. The primary endpoint of this study is freedom from local relapse (FFLR). Results At a median follow-up time of 26 months (range 7-92), the overall response rate for the 27 treated sites was 96%, with a complete response (CR) rate of 85% (n=23) and a partial response rate of 11% (n=3). Among all treated sites with CR, the 2-year FFLR was 100%, with no in-treatment field relapses. The 2-year freedom from regional relapse rate was 96% with 1 case of relapse within the ipsilateral orbit (outside of the treatment field). This patient underwent additional treatment with low-dose radiation of 4 Gy to the area of relapse achieving a CR and no evidence of disease at an additional 42 months of follow-up. Orbital radiation was well tolerated with only mild acute side effects (dry eye, conjunctivitis, transient periorbital edema) in 30% of treated sites without any reports of long-term toxicity. Conclusions Low-dose radiation with 2 Gy × 2 is effective and well tolerated in the treatment of indolent NHL of the ocular adnexa with high response rates and durable local control with the option of reirradiation in the case of locoregional relapse.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23726002</pmid><doi>10.1016/j.ijrobp.2013.04.035</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0360-3016
ispartof International journal of radiation oncology, biology, physics, 2013-08, Vol.86 (5), p.930-935
issn 0360-3016
1879-355X
1879-355X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7560946
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adult
Aged
Aged, 80 and over
EDEMA
Female
Follow-Up Studies
Hematology, Oncology and Palliative Medicine
Humans
Lymphoma - radiotherapy
Lymphoma, Non-Hodgkin - radiotherapy
LYMPHOMAS
Male
Middle Aged
Neoplasm Recurrence, Local
Orbital Neoplasms - radiotherapy
PATIENTS
RADIATION DOSES
Radiology
RADIOLOGY AND NUCLEAR MEDICINE
RADIOTHERAPY
Radiotherapy Dosage
Remission Induction
REVIEWS
SIDE EFFECTS
TOXICITY
title Low-Dose Radiation Therapy (2 Gy × 2) in the Treatment of Orbital Lymphoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T02%3A33%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low-Dose%20Radiation%20Therapy%20(2%20Gy%20%C3%97%202)%20in%20the%20Treatment%20of%20Orbital%20Lymphoma&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Fasola,%20Carolina%20E.,%20MD,%20MPH&rft.date=2013-08-01&rft.volume=86&rft.issue=5&rft.spage=930&rft.epage=935&rft.pages=930-935&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2013.04.035&rft_dat=%3Cproquest_pubme%3E1399934306%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1399934306&rft_id=info:pmid/23726002&rft_els_id=1_s2_0_S0360301613004641&rfr_iscdi=true